SERB Pharmaceuticals to Acquire Y-mAbs Therapeutics for ~$412M

Shots: SERB Pharmaceuticals has entered into a definitive merger agreement to acquire Y-mAbs, incl. its asset Danyelza (naxitamab-gqgk), strengthening its rare oncology portfolio As per the deal, SERB will acquire Y-mAbs for a total equity value of ~$412M, with its shareholders receiving $8.6/share in cash, delisting Y-mAbs from Nasdaq; closing expected in Q4’25 Additionally, Y-mAbs’ pipeline incl.…

ByRidhi RastogiAugust 6, 2025

NEWS

Alcon to Acquire STAAR Surgical Company for ~$1.5B

Shots: Alcon has entered into a definitive merger agreement to acquire STAAR Surgical Company incl. its asset EVO family of lenses (EVO ICL) As per the deal, Alcon will acquire STAAR for a total equity value of ~$1.5B, with its shareholders receiving $28/share in cash; the deal is expected to close within 6-12mos. EVO ICLs are…

ByRidhi RastogiAugust 5, 2025

NEWS

Concentra Biosciences Enters a Merger Agreement to Acquire iTeos Therapeutics

Shots: Concentra Biosciences has entered into a definitive merger agreement to acquire iTeos Therapeutics As per the deal, iTeos Therapeutics’ shareholders will receive $10.047 per share in cash, along with a non-transferable CVR, which entitles them to 100% of iTeos' net cash exceeding $475M at closing & 80% of net proceeds from the sale of…

ByRidhi RastogiJuly 22, 2025

NEWS

Sanofi to Acquire Vicebio for ~$1.6B

Shots: Sanofi has entered into an agreement to acquire Vicebio, expanding its respiratory vaccines pipeline & capabilities with Vicebio’s vaccine candidates (VXB-241 & VXB-251) & Molecular Clamp tech As per the deal, Vicebio will receive $1.15B upfront & ~$450M in development & regulatory milestones; closing is expected in Q4’25 Molecular Clamp tech stabilizes viral proteins…

ByRidhi RastogiJuly 22, 2025

NEWS

Becton Dickinson’s Biosciences & Diagnostic Solutions Business to Combine with Waters in a $17.5B Deal

Shots: BD to combine its Biosciences & Diagnostic Solutions business with Waters in a Reverse Morris Trust transaction As per the deal, BD shareholders will receive $4B in cash & a 39.2% stake in the combined company, while Waters will assume $4B in debt & retain 60.8%, with the total deal value of $17.5B reflecting cash,…

ByRidhi RastogiJuly 15, 2025

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (Jul 07, 2025 – Jul 11, 2025)   

This week, PharmaShots’ news was all about the updates on clinical trials, Regulatory, Pharma, MedTech, M&A, and Biosimilars. Check out our full report below:  PulseSight Therapeutics Reports First Patient Dosing with PST-611 in P-I (PST-611-CT1) Trial for Dry AMD/Geographic Atrophy  Read More: PulseSight Therapeutics BioAtla Presents Preliminary P-I Trial Data of BA3182 in Patients with…

ByRidhi RastogiJuly 11, 2025

NEWS

Merck to Acquire Verona Pharma for ~$10B

Shots: Merck has entered into a definitive agreement to acquire Verona Pharma incl. its asset Ohtuvayre (ensifentrine), expanding its cardio-pulmonary pipeline & portfolio As per the deal, Merck will acquire Verona Pharma for $107 per American Depository Share (ADS), each representing 8 ordinary Verona shares, for an aggregate of ~$10B; closing expected in Q4'25 Ohtuvayre…

ByRidhi RastogiJuly 10, 2025

NEWS

CB Biotechnology to Acquire Theratechnologies for ~$254M

Shots: CB Biotechnology has entered into a definitive agreement to acquire Theratechnologies, delisting it from public markets As per the deal, Theratechnologies’ shareholders will receive $3.01/share in cash & a non-tradeable CVR of $1.19/share tied to company milestones, with total CVR payments limited to $65M, making it an aggregate of $254M, assuming full CVR payout;…

ByRidhi RastogiJuly 3, 2025

NEWS

AbbVie to Acquire Capstan Therapeutics for ~$2.1B

Shots: AbbVie has entered into a definitive agreement to acquire Capstan Therapeutics, including its P-I CPTX2309 and proprietary tLNP platform for in vivo RNA delivery to treat B-cell-mediated autoimmune diseases As per the deal, Capstan will receive up to $2.1B in cash, pending customary closing conditions and regulatory approvals CPTX2309 is a tLNP delivering mRNA…

ByDipanshu DixitJuly 1, 2025

NEWS

Torrent Pharma to Acquire a Controlling Stake in JB Chemicals & Pharmaceuticals from KKR for ~$3B

Shots: Torrent Pharma acquired a controlling stake in JB Pharma from KKR in a strategic move to build a diversified healthcare platform As per the deal, KKR will receive INR 25,689 crore (~$3B) Equity Valuation on a fully diluted basis. Torrent will acquire a 46.39% stake in JB Pharma for ₹11,917 crore (~$1.39B) at INR 1,600…

ByDipanshu DixitJuly 1, 2025

SERB Pharmaceuticals to Acquire Y-mAbs Therapeutics for ~$412M

Alcon to Acquire STAAR Surgical Company for ~$1.5B

Concentra Biosciences Enters a Merger Agreement to Acquire iTeos Therapeutics

Sanofi to Acquire Vicebio for ~$1.6B

Becton Dickinson’s Biosciences & Diagnostic Solutions Business to Combine with Waters in a $17.5B Deal

PharmaShots Weekly Snapshots (Jul 07, 2025 – Jul 11, 2025)

Merck to Acquire Verona Pharma for ~$10B

CB Biotechnology to Acquire Theratechnologies for ~$254M

AbbVie to Acquire Capstan Therapeutics for ~$2.1B

Torrent Pharma to Acquire a Controlling Stake in JB Chemicals & Pharmaceuticals from KKR for ~$3B

Contact US

OUR INFORMATION

FOLLOW US